Fisher Asset Management LLC Has $30.13 Million Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Fisher Asset Management LLC trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 14.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 326,664 shares of the biotechnology company’s stock after selling 55,249 shares during the quarter. Fisher Asset Management LLC owned 0.53% of Blueprint Medicines worth $30,131,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Deutsche Bank AG lifted its holdings in Blueprint Medicines by 4.8% during the third quarter. Deutsche Bank AG now owns 82,567 shares of the biotechnology company’s stock worth $4,147,000 after acquiring an additional 3,805 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Blueprint Medicines by 1.6% during the 3rd quarter. Rhumbline Advisers now owns 85,202 shares of the biotechnology company’s stock valued at $4,279,000 after purchasing an additional 1,332 shares in the last quarter. Northern Trust Corp grew its position in shares of Blueprint Medicines by 0.5% in the 3rd quarter. Northern Trust Corp now owns 588,460 shares of the biotechnology company’s stock valued at $29,552,000 after purchasing an additional 2,763 shares during the period. Algert Global LLC bought a new stake in Blueprint Medicines during the 3rd quarter worth approximately $299,000. Finally, CHI Advisors LLC acquired a new stake in Blueprint Medicines during the 3rd quarter worth approximately $4,665,000.

Insider Buying and Selling

In other Blueprint Medicines news, insider Percy H. Carter sold 4,000 shares of the stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $105.13, for a total transaction of $420,520.00. Following the transaction, the insider now owns 41,895 shares in the company, valued at approximately $4,404,421.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Michael Landsittel sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $95.00, for a total value of $475,000.00. Following the completion of the transaction, the chief financial officer now owns 47,286 shares of the company’s stock, valued at $4,492,170. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Percy H. Carter sold 4,000 shares of the stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $105.13, for a total transaction of $420,520.00. Following the sale, the insider now owns 41,895 shares in the company, valued at $4,404,421.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 84,937 shares of company stock valued at $8,460,634. Insiders own 4.21% of the company’s stock.

Blueprint Medicines Stock Performance

Shares of BPMC stock opened at $103.87 on Tuesday. The stock has a market cap of $6.50 billion, a P/E ratio of -21.59 and a beta of 0.70. The company has a fifty day moving average price of $99.87 and a two-hundred day moving average price of $90.63. Blueprint Medicines Co. has a one year low of $43.89 and a one year high of $111.02. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.32. The firm had revenue of $96.12 million during the quarter, compared to analysts’ expectations of $82.58 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. As a group, equities analysts predict that Blueprint Medicines Co. will post -5.15 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on BPMC. Wedbush reiterated an “outperform” rating and issued a $110.00 price target on shares of Blueprint Medicines in a report on Friday, April 26th. Stephens assumed coverage on Blueprint Medicines in a report on Tuesday, May 14th. They set an “overweight” rating and a $140.00 target price for the company. Leerink Partnrs upgraded Blueprint Medicines from an “underperform” rating to a “market perform” rating in a report on Monday, May 6th. Barclays increased their price objective on Blueprint Medicines from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, May 3rd. Finally, StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $108.00.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.